The Role of Triglyceride to HDL Cholesterol Ratio in Sera as a Clinical Surrogate Marker for Cardiovascular Risk and Insulin Resistance in Patients with Metabolic Syndrome Cover

.blurhash-client-img { display: none !important; }

The Role of Triglyceride to HDL Cholesterol Ratio in Sera as a Clinical Surrogate Marker for Cardiovascular Risk and Insulin Resistance in Patients with Metabolic Syndrome

Journal of Biomedical and Clinical Research

Volume 14 (2021): Issue 2 (December 2021)

By: Silviya S. Ganeva, Ginka H. Rayanova, Katya N. Todorova, Tzvetan H. Lukanov and Svetla O. Blazheva

Open Access

|Jan 2022

Authors

Silviya S. Ganeva

doctorganeva@gmail.com

Clinic of Endocrinology and Metabolic Diseases, Dr. Georgi Stranski University Hospital - Pleven

Ginka H. Rayanova

Clinic of Endocrinology and Metabolic Diseases, Dr. Georgi Stranski University Hospital - Pleven

Katya N. Todorova

Clinic of Endocrinology and Metabolic Diseases, Dr. Georgi Stranski University Hospital - Pleven

Tzvetan H. Lukanov

Medico-Diagnostic Laboratory of Immunology, Dr. Georgi Stranski University Hospital - Pleven

Svetla O. Blazheva

Medico-Diagnostic Laboratory of Immunology, Dr. Georgi Stranski University Hospital - Pleven

DOI: https://doi.org/10.2478/jbcr-2021-0012 | Journal eISSN: 1313-9053

Journal RSS Feed

Language: English

Page range: 162 - 168

Submitted on: Jan 28, 2021

|

Accepted on: Jul 8, 2021

|

Published on: Jan 18, 2022

Published by: Sciendo

In partnership with: Paradigm Publishing Services

Publication frequency: 2 issues per year

Keywords:

metabolic syndrome,

insulin resistance,

atherogenic index,

Related subjects:

Clinical medicine,

Clinical medicine, other,

Clinical pharmacy

© 2022 Silviya S. Ganeva, Ginka H. Rayanova, Katya N. Todorova, Tzvetan H. Lukanov, Svetla O. Blazheva, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 14 (2021): Issue 2 (December 2021)Next article